Klinik für Allgemein-, Viszeral- und Kinderchirurgie

[["dc.bibliographiccitation.firstpage","810"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology, Biology, Physics"],["dc.bibliographiccitation.lastpage","816"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Wenz, Frederik"],["dc.contributor.author","Dinter, Dietmar J."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hohenberger, Peter"],["dc.date.accessioned","2020-11-23T13:34:19Z"],["dc.date.available","2020-11-23T13:34:19Z"],["dc.date.issued","2009-11-01"],["dc.description.abstract","To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)."],["dc.identifier.doi","10.1016/j.ijrobp.2008.11.032"],["dc.identifier.pmid","19307066"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69018"],["dc.language.iso","en"],["dc.relation.eissn","1879-355X"],["dc.relation.issn","0360-3016"],["dc.title","Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","10554"],["dc.bibliographiccitation.issue","15, Suppl."],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Menge, Franka"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Mathew, Monika"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Reichardt, Peter"],["dc.contributor.author","Wardelmann, Eva"],["dc.date.accessioned","2020-11-23T13:33:34Z"],["dc.date.available","2020-11-23T13:33:34Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1200/jco.2014.32.15_suppl.10554"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69010"],["dc.relation.issn","0732-183X"],["dc.relation.issn","1527-7755"],["dc.title","Metastatic pattern of late metastases of gastrointestinal stromal tumors and the contribution radiation therapy for disease control"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S689"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","S690"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Raut, C."],["dc.contributor.author","Miceli, R."],["dc.contributor.author","Strauss, D."],["dc.contributor.author","Swallow, C."],["dc.contributor.author","Hohenberger, P."],["dc.contributor.author","Van Coevorden, F."],["dc.contributor.author","Rutkowski, P."],["dc.contributor.author","Fiore, M."],["dc.contributor.author","Callegaro, D."],["dc.contributor.author","Casali, P."],["dc.contributor.author","Haas, R."],["dc.contributor.author","Hayes, A."],["dc.contributor.author","Honore, C."],["dc.contributor.author","Cannell, A."],["dc.contributor.author","Jakob, J."],["dc.contributor.author","Szacht, M."],["dc.contributor.author","Fairweather, M."],["dc.contributor.author","Pollock, R."],["dc.contributor.author","Bonvalot, S."],["dc.contributor.author","Gronchi, A."],["dc.date.accessioned","2020-11-23T13:33:03Z"],["dc.date.available","2020-11-23T13:33:03Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1016/S0959-8049(16)31879-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69005"],["dc.relation.issn","0959-8049"],["dc.title","3404 External validation of a nomogram predicting disease-free (DFS) and overall survival (OS) in patients (pts) with primary retroperitoneal sarcoma (pRPS)"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","10560"],["dc.bibliographiccitation.issue","15, Suppl."],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Mussi, C."],["dc.contributor.author","Jakob, J."],["dc.contributor.author","Wardelmann, E."],["dc.contributor.author","Reichardt, P."],["dc.contributor.author","Casali, P. G."],["dc.contributor.author","Fiore, M."],["dc.contributor.author","Collini, P."],["dc.contributor.author","Gronchi, A."],["dc.contributor.author","Hohenberger, P."],["dc.date.accessioned","2020-11-23T13:34:30Z"],["dc.date.available","2020-11-23T13:34:30Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1200/jco.2008.26.15_suppl.10560"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69021"],["dc.relation.issn","0732-183X"],["dc.relation.issn","1527-7755"],["dc.title","Gastrointestinal stromal tumor of the rectum and rectovaginal space: A retrospective review"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","343"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Der Onkologe"],["dc.bibliographiccitation.lastpage","351"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Jo, P."],["dc.contributor.author","Jakob, Jens"],["dc.date.accessioned","2021-04-14T08:29:10Z"],["dc.date.available","2021-04-14T08:29:10Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1007/s00761-021-00903-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82822"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1433-0415"],["dc.relation.issn","0947-8965"],["dc.title","Toxizität und Effektivität lokoregionaler Chemotherapien"],["dc.title.translated","Toxicity and effectiveness of locoregional chemotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","S004520682100883X"],["dc.bibliographiccitation.firstpage","105505"],["dc.bibliographiccitation.journal","Bioorganic Chemistry"],["dc.contributor.author","Lier, Svenja"],["dc.contributor.author","Sellmer, Andreas"],["dc.contributor.author","Orben, Felix"],["dc.contributor.author","Heinzlmeir, Stephanie"],["dc.contributor.author","Krauß, Lukas"],["dc.contributor.author","Schneeweis, Christian"],["dc.contributor.author","Hassan, Zonera"],["dc.contributor.author","Schneider, Carolin"],["dc.contributor.author","Schäfer, Arlette"],["dc.contributor.author","Pongratz, Herwig"],["dc.contributor.author","Schneider, Günter"],["dc.date.accessioned","2021-12-01T09:23:03Z"],["dc.date.available","2021-12-01T09:23:03Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.bioorg.2021.105505"],["dc.identifier.pii","S004520682100883X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94548"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.issn","0045-2068"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","959"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Annals of Surgery"],["dc.bibliographiccitation.lastpage","964"],["dc.bibliographiccitation.volume","267"],["dc.contributor.author","MacNeill, Andrea J."],["dc.contributor.author","Gronchi, Alessandro"],["dc.contributor.author","Miceli, Rosalba"],["dc.contributor.author","Bonvalot, Sylvie"],["dc.contributor.author","Swallow, Carol J."],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Van Coevorden, Frits"],["dc.contributor.author","Rutkowski, Piotr"],["dc.contributor.author","Callegaro, Dario"],["dc.contributor.author","Hayes, Andrew J."],["dc.contributor.author","Honoré, Charles"],["dc.contributor.author","Fairweather, Mark"],["dc.contributor.author","Cannell, Amanda"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Haas, Rick L."],["dc.contributor.author","Szacht, Milena"],["dc.contributor.author","Fiore, Marco"],["dc.contributor.author","Casali, Paolo G."],["dc.contributor.author","Pollock, Raphael E."],["dc.contributor.author","Barretta, Francesco"],["dc.contributor.author","Raut, Chandrajit P."],["dc.contributor.author","Strauss, Dirk C."],["dc.date.accessioned","2020-11-23T13:32:06Z"],["dc.date.available","2020-11-23T13:32:06Z"],["dc.date.issued","2018"],["dc.description.abstract","To investigate the safety of radical resection for retroperitoneal sarcoma (RPS)."],["dc.identifier.doi","10.1097/SLA.0000000000002250"],["dc.identifier.pmid","28394870"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/68992"],["dc.language.iso","en"],["dc.relation.eissn","1528-1140"],["dc.relation.issn","0003-4932"],["dc.title","Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Cell Biology and Toxicology"],["dc.contributor.author","Kiweler, Nicole"],["dc.contributor.author","Schwarz, Helena"],["dc.contributor.author","Nguyen, Alexandra"],["dc.contributor.author","Matschos, Stephanie"],["dc.contributor.author","Mullins, Christina"],["dc.contributor.author","Piée-Staffa, Andrea"],["dc.contributor.author","Brachetti, Christina"],["dc.contributor.author","Roos, Wynand P."],["dc.contributor.author","Schneider, Günter"],["dc.contributor.author","Linnebacher, Michael"],["dc.contributor.author","Krämer, Oliver H."],["dc.date.accessioned","2022-06-01T09:39:57Z"],["dc.date.available","2022-06-01T09:39:57Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract The epigenetic modifier histone deacetylase-2 (HDAC2) is frequently dysregulated in colon cancer cells. Microsatellite instability (MSI), an unfaithful replication of DNA at nucleotide repeats, occurs in about 15% of human colon tumors. MSI promotes a genetic frameshift and consequently a loss of HDAC2 in up to 43% of these tumors. We show that long-term and short-term cultures of colorectal cancers with MSI contain subpopulations of cells lacking HDAC2. These can be isolated as single cell-derived, proliferating populations. Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice. HDAC2-positive and HDAC2-negative RKO cells respond similarly to pharmacological inhibitors of the class I HDACs HDAC1/HDAC2/HDAC3. In contrast to this similarity, HDAC2-negative and HDAC2-positive RKO cells undergo differential cell cycle arrest and apoptosis induction in response to the frequently used chemotherapeutic 5-fluorouracil, which becomes incorporated into and damages RNA and DNA. 5-fluorouracil causes an enrichment of HDAC2-negative RKO cells in vitro and in a subset of primary colorectal tumors in mice. 5-fluorouracil induces the phosphorylation of KAP1, a target of the checkpoint kinase ataxia-telangiectasia mutated (ATM), stronger in HDAC2-negative cells than in their HDAC2-positive counterparts. Pharmacological inhibition of ATM sensitizes RKO cells to cytotoxic effects of 5-fluorouracil. These findings demonstrate that HDAC2 and ATM modulate the responses of colorectal cancer cells towards 5-FU. Graphical abstract"],["dc.description.sponsorship"," wilhelm sander-stiftung"],["dc.description.sponsorship","brigitte und dr. konstanze wegener-stiftung"],["dc.description.sponsorship"," deutsche forschungsgemeinschaft"],["dc.description.sponsorship"," Universitätsmedizin der Johannes Gutenberg-Universität Mainz 501100014584"],["dc.identifier.doi","10.1007/s10565-022-09731-3"],["dc.identifier.pii","9731"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108600"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","1573-6822"],["dc.relation.issn","0742-2091"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","431"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Der Pathologe"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Jakob, J."],["dc.contributor.author","Hohenberger, P."],["dc.date.accessioned","2020-11-23T13:31:12Z"],["dc.date.available","2020-11-23T13:31:12Z"],["dc.date.issued","2019-07"],["dc.description.abstract","Soft-tissue sarcomas are rare malignant tumors. Surgery remains the most important treatment modality. Neoadjuvant and/or adjuvant chemo- and radiotherapy may be administered to improve the local and systemic outcome. Advances in oncological and reconstructive surgery, combined with the use of multimodal therapies, have made mutilating surgery rare events in extremity sarcomas. In retroperitoneal sarcomas, local recurrences are life-threatening events and multivisceral resection has become the standard surgical procedure. The subjects of this review are diagnostics, multimodal therapy, and resection strategy from a surgical point of view."],["dc.identifier.doi","10.1007/s00292-019-0631-2"],["dc.identifier.pmid","31240451"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/68982"],["dc.language.iso","other"],["dc.relation.eissn","1432-1963"],["dc.relation.issn","0172-8113"],["dc.title","Prinzipien der Sarkomchirurgie"],["dc.title.alternative","Principles of sarcoma surgery"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","301"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","312"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Golcher, Henriette"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Richter, Stephan"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2021-06-01T09:42:10Z"],["dc.date.available","2021-06-01T09:42:10Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. Methods: From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. Results: Patients and survivors (n = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28–8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67–9.21). Conclusion:Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development."],["dc.identifier.doi","10.1159/000516262"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85163"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]